Conditions: Myelodysplastic Syndromes
Keywords: myelodysplastic syndromes (MDS) neoplastic stem cell disorders refractory cytopenias dysplastic morphological features acute myeloid leukemia (AML)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
The primary purpose of this research study is to assess whether the participant's disease, Myelodysplastic Syndromes (MDS), responds favorably to INCB024360. The study will also evaluate the long-term outcomes of the participant's disease after they have finished taking INCB024360.

Detailed description:

Arms:
arm 1: Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.

Interventions: intervention 1: INCB024360
Intervention descriptions: intervention 1: INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.

Protocol document: